Company intelligence / Profile preview

Aviceda Therapeutics

Cambridge, Massachusetts, United Statesavicedarx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

AVD-104 has demonstrated positive safety and early clinical efficacy in patients with geographic atrophy secondary to AMD. In Part I of the Phase II/III SIGLEC trial, AVD-104 was well-tolerated with no drug-related serious adverse events. Substantial slowing of GA lesion growth and functional improvement were observed at three months after a single dose. The pivotal Part II trial is fully enrolled; primary endpoint data are expected in late-2025[10][7].

Therapeutic areas: OphthalmologyImmunologyOtherOncologyNeurology
Modalities: glycan-coated nanoparticlesimmunomodulatorsglycobiology-based therapeutics
Industry: Biotech

Drug pipeline

2 assets

avd-104

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aviceda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aviceda Therapeutics.

Explore the full profile